Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple myeloma.

Robert A Kyle1, S Vincent Rajkumar

  • 1Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. kyle.robert@mayo.edu

Blood
|March 12, 2008
PubMed
Summary
This summary is machine-generated.

Multiple myeloma, a plasma cell cancer, has seen significant treatment advancements since its first description in 1844. This review details the historical evolution of therapies, including drug development and stem-cell transplantation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

James Allison and Cancer Immunotherapy.

Mayo Clinic proceedings·2020
Same author

Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.

Blood advances·2020
Same author

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?

Blood cancer journal·2020
Same author

Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic.

Mayo Clinic proceedings·2020
Same author

Razi: Critical Thinker, and Pioneer of Infectious Disease and Ophthalmology.

Mayo Clinic proceedings·2020
Same author

Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.

Clinical lymphoma, myeloma & leukemia·2020
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Medical History

Background:

  • Multiple myeloma is a significant hematologic cancer, comprising over 10% of all such malignancies.
  • Characterized as a clonal plasma cell malignancy, its clinical and scientific understanding has evolved considerably.

Observation:

  • This paper provides a historical review of multiple myeloma, tracing its journey from the initial case report in 1844 to contemporary understanding.
  • The review examines the progression of treatment modalities, including chemotherapy, targeted therapies, and stem-cell transplantation.

Findings:

  • Key discoveries and experimental study outcomes have driven the evolution of diagnostic and therapeutic strategies for multiple myeloma.
  • The development of novel therapeutic agents has significantly impacted patient outcomes and treatment paradigms.

Related Experiment Videos

Implications:

  • Understanding the historical context of multiple myeloma research is crucial for appreciating current treatment advancements.
  • This historical perspective informs future research directions and the development of more effective therapies for this plasma cell malignancy.